[go: up one dir, main page]

IT201700058311A1 - Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini - Google Patents

Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Info

Publication number
IT201700058311A1
IT201700058311A1 IT102017000058311A IT201700058311A IT201700058311A1 IT 201700058311 A1 IT201700058311 A1 IT 201700058311A1 IT 102017000058311 A IT102017000058311 A IT 102017000058311A IT 201700058311 A IT201700058311 A IT 201700058311A IT 201700058311 A1 IT201700058311 A1 IT 201700058311A1
Authority
IT
Italy
Prior art keywords
vitamin
bacterial
ester
treatment
formulation based
Prior art date
Application number
IT102017000058311A
Other languages
English (en)
Inventor
Giorgio Panin
Original Assignee
Bio Lo Ga Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Lo Ga Srl filed Critical Bio Lo Ga Srl
Priority to IT102017000058311A priority Critical patent/IT201700058311A1/it
Priority to DK18727014.5T priority patent/DK3630092T3/da
Priority to EA201992190A priority patent/EA201992190A1/ru
Priority to RS20220631A priority patent/RS63347B1/sr
Priority to SM20220274T priority patent/SMT202200274T1/it
Priority to ES18727014T priority patent/ES2919423T3/es
Priority to US16/613,526 priority patent/US20200360339A1/en
Priority to GEAP202015201A priority patent/GEAP202015201A/en
Priority to LTEPPCT/EP2018/063926T priority patent/LT3630092T/lt
Priority to MX2019013559A priority patent/MX389883B/es
Priority to SI201830680T priority patent/SI3630092T1/sl
Priority to MA48936A priority patent/MA48936B1/fr
Priority to CN201880027971.1A priority patent/CN110650737A/zh
Priority to PL18727014.5T priority patent/PL3630092T3/pl
Priority to EP18727014.5A priority patent/EP3630092B1/en
Priority to GEAP201815201A priority patent/GEP20207179B/en
Priority to HRP20220808TT priority patent/HRP20220808T1/hr
Priority to PCT/EP2018/063926 priority patent/WO2018219862A1/en
Priority to PT187270145T priority patent/PT3630092T/pt
Priority to CA3061568A priority patent/CA3061568C/en
Priority to BR112019023962A priority patent/BR112019023962A8/pt
Priority to HUE18727014A priority patent/HUE059185T2/hu
Priority to AU2018275487A priority patent/AU2018275487B2/en
Publication of IT201700058311A1 publication Critical patent/IT201700058311A1/it
Priority to CL2019003254A priority patent/CL2019003254A1/es
Priority to US16/683,684 priority patent/US11234958B2/en
Priority to US17/231,761 priority patent/US20210228541A1/en
Priority to CY20221100480T priority patent/CY1125414T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
IT102017000058311A 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini IT201700058311A1 (it)

Priority Applications (27)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
BR112019023962A BR112019023962A8 (pt) 2017-05-29 2018-05-28 Formulação à base de vitamina e ou um éster da mesma para tratamento de biofilmes bacterianos e fúngicos
PL18727014.5T PL3630092T3 (pl) 2017-05-29 2018-05-28 Preparat na bazie witaminy e lub jej estru do leczenia biofilmów bakteryjnych i grzybiczych
RS20220631A RS63347B1 (sr) 2017-05-29 2018-05-28 Formulacija na bazi vitamina e ili njegovog estra za lečenje bakterijskih i gljivičnih biofilmova
SM20220274T SMT202200274T1 (it) 2017-05-29 2018-05-28 Formulazione a base di vitamina e o di un suo estere per il trattamento di biofilm batterici e fungini
ES18727014T ES2919423T3 (es) 2017-05-29 2018-05-28 Formulación basada en vitamina E o un éster de la misma para tratar biopelículas bacterianas o fúngicas
US16/613,526 US20200360339A1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
GEAP202015201A GEAP202015201A (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or ester thereof for treating bacterial and fungal biofilms
LTEPPCT/EP2018/063926T LT3630092T (lt) 2017-05-29 2018-05-28 Kompozicija, kurios pagrindą sudaro vitaminas e arba jo esteris, skirta bakterijų ir grybelių bioplėvelėms gydyti
MX2019013559A MX389883B (es) 2017-05-29 2018-05-28 Formulacion basada en vitamina e o un ester de la misma para tratar biopeliculas bacterianas y fungicas
SI201830680T SI3630092T1 (sl) 2017-05-29 2018-05-28 Formulacija na osnovi vitamina E ali njegovega estra za tretiranje bakterijskih in glivičnih biofilmov
MA48936A MA48936B1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques
GEAP201815201A GEP20207179B (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or ester thereof for treating bacterial and fungal biofilms
DK18727014.5T DK3630092T3 (da) 2017-05-29 2018-05-28 Formulering på basis af vitamin E eller en ester deraf til behandling af bakterie- og svampebiofilm
EP18727014.5A EP3630092B1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
CN201880027971.1A CN110650737A (zh) 2017-05-29 2018-05-28 基于维生素e或其酯的用于处理细菌和真菌生物膜的制剂
HRP20220808TT HRP20220808T1 (hr) 2017-05-29 2018-05-28 Formulacija na bazi vitamina e ili njegovog estera za liječenje bakterijskih i gljivičnih biofilmova
PCT/EP2018/063926 WO2018219862A1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
PT187270145T PT3630092T (pt) 2017-05-29 2018-05-28 Formulação à base de vitamina e ou um éster da mesma para tratar biofilmes bacterianos e fúngicos
CA3061568A CA3061568C (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
EA201992190A EA201992190A1 (ru) 2017-05-29 2018-05-28 Состав на основе витамина е или его сложного эфира для лечения бактериальных и грибковых биопленок
HUE18727014A HUE059185T2 (hu) 2017-05-29 2018-05-28 Készítmény, amely e vitaminon vagy észteren alapul bakteriális vagy gomba eredetû biofilmek kezelésére
AU2018275487A AU2018275487B2 (en) 2017-05-29 2018-05-28 Formulation based on vitamin E or an ester thereof for treating bacterial and fungal biofilms
CL2019003254A CL2019003254A1 (es) 2017-05-29 2019-11-13 Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.
US16/683,684 US11234958B2 (en) 2017-05-29 2019-11-14 Formulation based on vitamin E or an ester thereof for treating bacterial and fungal biofilms
US17/231,761 US20210228541A1 (en) 2017-05-29 2021-04-15 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms
CY20221100480T CY1125414T1 (el) 2017-05-29 2022-07-12 Σκευασμα με βαση τη βιταμινη ε ή εναν εστερα αυτης για την αντιμετωπιση βακτηριακων και μυκητιασικων βιομεμβρανων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Publications (1)

Publication Number Publication Date
IT201700058311A1 true IT201700058311A1 (it) 2018-11-29

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Country Status (24)

Country Link
US (3) US20200360339A1 (it)
EP (1) EP3630092B1 (it)
CN (1) CN110650737A (it)
AU (1) AU2018275487B2 (it)
BR (1) BR112019023962A8 (it)
CA (1) CA3061568C (it)
CL (1) CL2019003254A1 (it)
CY (1) CY1125414T1 (it)
DK (1) DK3630092T3 (it)
EA (1) EA201992190A1 (it)
ES (1) ES2919423T3 (it)
GE (2) GEAP202015201A (it)
HR (1) HRP20220808T1 (it)
HU (1) HUE059185T2 (it)
IT (1) IT201700058311A1 (it)
LT (1) LT3630092T (it)
MA (1) MA48936B1 (it)
MX (1) MX389883B (it)
PL (1) PL3630092T3 (it)
PT (1) PT3630092T (it)
RS (1) RS63347B1 (it)
SI (1) SI3630092T1 (it)
SM (1) SMT202200274T1 (it)
WO (1) WO2018219862A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
EP4149624A1 (en) * 2020-05-11 2023-03-22 Katholieke Universiteit Leuven Use of di- and tricarboxylic fatty acids in the prevention of biofilm formation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US6280752B1 (en) * 1998-09-25 2001-08-28 Giorgio Panin Vitamin E acetate-based hydrophobic gel formulation for topical application
WO2010121081A1 (en) * 2009-04-15 2010-10-21 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
WO2017050668A1 (en) * 2015-09-25 2017-03-30 Bio.Lo.Ga. S.R.L. Hydrophobic gel based on vitamin e free from silicone products for topical application
WO2017119009A1 (en) * 2016-01-08 2017-07-13 Eon Medica S.R.L. Vitamin e phosphate or acetate for use in the treatment and prevention of biofilm infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US6280752B1 (en) * 1998-09-25 2001-08-28 Giorgio Panin Vitamin E acetate-based hydrophobic gel formulation for topical application
WO2010121081A1 (en) * 2009-04-15 2010-10-21 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
WO2017050668A1 (en) * 2015-09-25 2017-03-30 Bio.Lo.Ga. S.R.L. Hydrophobic gel based on vitamin e free from silicone products for topical application
WO2017119009A1 (en) * 2016-01-08 2017-07-13 Eon Medica S.R.L. Vitamin e phosphate or acetate for use in the treatment and prevention of biofilm infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIDE CAMPOCCIA ET AL: ")lactic acid blended with vitamin E: Toward gentle anti-infective biomaterials", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART A, vol. 103, no. 4, 4 August 2014 (2014-08-04), HOBOKEN, NY, US, pages 1447 - 1458, XP055303081, ISSN: 1549-3296, DOI: 10.1002/jbm.a.35284 *
SUMITKUMAR JAGANI ET AL: "Effects of phenol and natural phenolic compounds on biofilm formation by Pseudomonas aeruginosa", BIOFOULING: THE JOURNAL OF BIOADHESION AND BIOFILM RESEARCH, vol. 25, no. 4, 3 March 2009 (2009-03-03), GN, pages 321 - 324, XP055451744, ISSN: 0892-7014, DOI: 10.1080/08927010802660854 *

Also Published As

Publication number Publication date
ES2919423T3 (es) 2022-07-26
PL3630092T3 (pl) 2022-09-12
HUE059185T2 (hu) 2022-10-28
BR112019023962A2 (pt) 2020-06-09
WO2018219862A1 (en) 2018-12-06
US20200121638A1 (en) 2020-04-23
LT3630092T (lt) 2022-06-27
GEAP201815201A (it) 2020-07-27
DK3630092T3 (da) 2022-06-20
CL2019003254A1 (es) 2020-07-03
EP3630092A1 (en) 2020-04-08
AU2018275487A1 (en) 2019-11-07
US11234958B2 (en) 2022-02-01
HRP20220808T1 (hr) 2022-09-30
SI3630092T1 (sl) 2022-08-31
BR112019023962A8 (pt) 2022-07-05
CY1125414T1 (el) 2025-05-09
MX2019013559A (es) 2022-02-03
AU2018275487B2 (en) 2024-03-14
US20210228541A1 (en) 2021-07-29
SMT202200274T1 (it) 2022-07-21
GEP20207179B (en) 2020-11-10
MA48936A (fr) 2020-04-08
US20200360339A1 (en) 2020-11-19
CN110650737A (zh) 2020-01-03
CA3061568A1 (en) 2018-12-06
EP3630092B1 (en) 2022-04-13
MX389883B (es) 2025-03-20
CA3061568C (en) 2024-02-13
EA201992190A1 (ru) 2020-09-03
PT3630092T (pt) 2022-06-02
RS63347B1 (sr) 2022-07-29
MA48936B1 (fr) 2022-08-31
GEAP202015201A (en) 2020-07-27

Similar Documents

Publication Publication Date Title
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP4249563C0 (en) COATINGS
IL271550B (en) A cyclic coumarin-like compound as a mek inhibitor and its use
IL284799A (en) Tyk2 inhibitors and uses thereof
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
EP3515608C0 (en) DROPLET EJECTION COATINGS
DK3612524T3 (da) 6-pyrimidin-isoindol-derivat som erk1/2-inhibitor
DK3456787T3 (da) Vandbaseret coatingformulering
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
FI3679275T3 (fi) Korkean reduktion käsittävä hihnakäyttöinen lineaarikäyttölaite
EP3333237A4 (en) URETHANE-BASED ADHESIVE COMPOSITION
HUE057923T2 (hu) Bútormeghajtás
IL287560A (en) Mrna formulation
DK3712162T3 (da) Smac-mimetica anvendt som iap-inhibitorer og anvendelse deraf
IT201700058311A1 (it) Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
IL280138A (en) Aerosolisable formulation
EP3836980C0 (en) FORMULATION
EP4190324A4 (en) NUTRITION FORMULATION
EP3867239C0 (en) QUINONE REDUCTASE 2 INHIBITOR COMPOUNDS AND RELATED USES
SG11202102727RA (en) Immunoproteasome inhibitor formulation
EP3815704A4 (en) FORMULATION CONTAINING EMRICASAN
PL3600278T3 (pl) Statyna w profilaktyce/ograniczaniu uszkodzeń związanych z niedokrwieniem